Sartorius Stedim Biotech SA
DIM: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€844.00 | Qksv | Xwdcmsdykj |
Sartorius Stedim Earnings: COVID-19 Demand Retreats Along With Profits
Wide-moat Sartorius Stedim (Sartorius Ag's bioprocess subsidiary) revealed a tough start to 2023, as previous COVID-19 tailwinds turned into headwinds. Management maintained its guidance for 2023, though. And while we have tinkered with our near-term assumptions, these minor changes did not materially affect our EUR 306 fair value estimate.